Eli Lilly has updated its Trulicity label to now include use in combination with basal insulin for adults with type 2 diabetes.
The U.S. Food and Drug Administration (FDA) included the changes to the approved product labeling to reflect this important information for prescribers.
Adults with type 2 diabetes now have the option to use Trulicity, with its powerful efficacy in a once-weekly, easy-to-use pen, said the vice president, said Sherry Martin, vice president, Global Medical Affairs, Lilly Diabetes.
Trulicity was first approved in September 2014 as a once-weekly injectable prescription medicine to improve blood sugar (glucose) in adults with type 2 diabetes.
The label was also updated to include results from the AWARD-8 clinical trial, a Phase 3b randomized, double-blind, placebo-controlled, 24-week study that evaluated the efficacy and safety of Trulicity 1.5 mg as an add-on to sulfonylurea compared to placebo plus sulfonylurea.2